Loading
A phase 3 trial of Olaparib, Abiraterone acetate in prostate cancer, run by AstraZeneca, active and no longer recruiting.
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) is a phase 3 interventional study registered as NCT05171816 by AstraZeneca, with 110 participants enrolled, started 2021-06-24 and due to reach its primary completion in 2024-01-22. Interventions recorded: olaparib, abiraterone acetate. Conditions listed: Metastatic Castration-resistant Prostate Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
110 enrolled.
95% CI 12.06 to 22.11; Figures from the ClinicalTrials.gov results section (first posted 2025-06-29), not from a publication · NA - Not calculated, estimates cannot be calculated due to too few events
Source95% CI 27.83 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-06-29), not from a publication · NA - Not calculated, estimates cannot be calculated due to too few events
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Radiological Progression Free Survival (rPFS)primary | Olaparib 300 mg bd + Abiraterone 1000 mg qd | 54 | 14.75 months | 1.43 (0.83 to 2.48) | 0.2592 | link |
| Placebo bd + Abiraterone 1000 mg qd | 56 | NA - Not calculated, estimates cannot be calculated due to too few events | ||||
| Overall Survival (OS) | Olaparib 300 mg bd + Abiraterone 1000 mg qd | 54 | 27.83 months | 1.14 (0.57 to 2.29) | 0.7251 | link |
| Placebo bd + Abiraterone 1000 mg qd | 56 | NA - Not calculated, estimates cannot be calculated due to too few events |
Shares PARP inhibitors, Olaparib, Metastatic castration-resistant prostate cancer, AstraZeneca.
Shares Prescribe a quarter dose of abiraterone with breakfast, Abiraterone acetate, Prostate cancer.
Shares Prescribe a quarter dose of abiraterone with breakfast, Abiraterone acetate, Prostate cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares Prescribe a quarter dose of abiraterone with breakfast, Abiraterone acetate, PARP inhibitors, Olaparib.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares Abiraterone acetate, PARP inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.